Blog
RSS FeedPosted by Michael Wonder on 20 Mar 2025
Health Economics Methods Advisory Group selects first area for study: assessing treatment benefits appropriate to consider in HTA decision-making
18 March 2025 - The US based ICER, England’s NICE and Canada’s Drug Agency have selected the first research topic ...
Posted by Michael Wonder on 29 May 2023
A review of HTA guidelines on societal and novel value elements
25 May 2023 - Health technology assessment organisations vary in terms of how they conduct assessments. ...
Posted by Michael Wonder on 22 Oct 2022
Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body
20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years. ...
Posted by Michael Wonder on 27 Jan 2022
The certainty of uncertainty in health technology assessment
26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...
Posted by Michael Wonder on 17 May 2021
Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?
15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 07 Nov 2020
A health opportunity cost threshold for cost effectiveness analysis in the United State
3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...
Posted by Michael Wonder on 05 Jul 2020
Beyond the numbers: a critique of quantitative multi-criteria decision analysis
1 July 2020 - When setting priorities for health, there is broad agreement that a range of social values and ethical ...
Posted by Michael Wonder on 03 Jun 2020
Paying for value from costly medical technologies: a framework for applying value-based payment reforms
2 June 2020 - Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising ...
Posted by Michael Wonder on 02 Jun 2020
Traditional cost effectiveness formulas and precision medicines
1 June 2020 - Cost effectiveness analyses, which are often conducted to evaluate new medicines, use a standardised framework to ...
Posted by Michael Wonder on 15 May 2020
Putting a dollar value on life? Governments already do
11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 11 Dec 2019
Expanding use of multi-criteria decision analysis for health technology assessment
11 December 2019 - As America’s health care system continues to evolve, it is critical that our perception of care ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 21 Aug 2019
ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures
21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...